Xentuzumab
(Entinostat)Phase 3Small molecule
Entinostat is being studied as a cancer treatment, particularly for certain blood cancers and solid tumors. It works by helping the immune system fight cancer cells and can make cancer cells more vulnerable to other treatments.[1] Xentuzumab is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Xentuzumab is one of 185 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
8
Indications
72
Total Trials
14
Active Trials
184
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Xentuzumab
SSyndax Pharmaceuticals
Phase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic
CCephalon
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Bisphosphonate
AmgenPreclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer17 trials
Show 14 more trials
An Open-Label, Single-Center, Exploratory Phase Ib/II Clinical Study of Entinostat Combined With Pyrotinib Plus Endocrine Therapy in Patients With Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Preclinical·NCT07708194·94 enrolled
Lymphoma5 trials
Non-Small Cell Lung Cancer5 trials
Lung Cancer2 trials
32 more indications
Renal Cell Carcinoma2 trials
Chronic Myelomonocytic Leukemia2 trials
Metastatic Colorectal Cancer2 trials
Adult Subject2 trials
Acute Lymphoblastic Leukemia2 trials
Pancreatic Adenocarcinoma2 trials
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Withdrawn·—·Phase 1·NCT03760614
Myelodysplastic Syndrome2 trials
Bladder Cancer2 trials
Anatomic Stage III Breast Cancer AJCC v82 trials
Phase II1 trial
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01928576·143 enrolled
Advanced Solid Tumors1 trial
Non-Small Cell Lung Carcinoma1 trial
Acute Myeloid Leukemia1 trial
Impaired Renal Function1 trial
Fallopian Tube Cancer1 trial
Ovarian Cancer1 trial
Endometrial Cancer1 trial
Esophageal Cancer1 trial
Advanced NSCLC1 trial
Metastatic Melanoma1 trial
Newly Diagnosed1 trial
Patients With Advanced Solid Tumors1 trial
Melanoma1 trial
Tics1 trial
Recurrent or Refractory Solid Tumors1 trial
Oropharyngeal Cancer1 trial
Clear Cell Renal Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Entinostat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Histone Deacetylase Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSyndax Pharmaceuticals